Table 1.

DNA OVs.

Family and Type Species	Name	Viral Genetic Modification	Exploited Cancer Pathway	Combination with Other Therapeutics	Refs	Models
Adenoviridae, Human Adenovirus C	dl1520 (ONYX-015)	E1B-55kDa deletion	p53 deficiency	Doxorubicin, Paclitaxel	66	in vitro and mouse models
				Ionizing Radiation (IR)	68
				Lovastatin	72
	dl922-947	E1A-CR2 deletion	pRb deficiency	Bevacizumab	73	in vitro and mouse models
				AZD1152	82
				IR	83
				Olaparib	84
	HILMI	TCF/β-catenin responsive promoter insertion	Wnt/β-catenin hyper-activation	NO	93	in vitro and mouse models
	ONYX-411	E2F promoter insertion controls E1A and E4 gene expression E1A-CR2 deletion	E2F hyper-expression pRb deficiency	NO	94	in vitro and mouse models
	dl309	E3 10.4K, 14.5 K, 14.7 K deletion E3 6.7K mutation		NO	95	in vitro
	VB-111 (non-replicative)	E1 deletion and insertion of Fas-c gene under a modified PPE-1 promoter		NO	120	mouse models
Poxviridae, Vaccinia Virus	VACV	EGFP insertion	AKT hyperactivation	NO	99	in vitro
	GLV-1h68	Insertion of RUC-GFP, β -galactosidase, β-glucuronidase into F14.5L, J2R and A56R loci of the viral genome, respectively	AKT hyperactivation	NO	101-103	in vitro and mouse models
Poxviridae, Tanapox Virus Myxoma Virus	TANV MYXV	EGFP insertion	AKT hyperactivation	NO	99	in vitro
Herpesviridae, Human herpesvirus 1	NV1023	HSV2 genes (US2-2 and US2-5) insertion in the UL/S junction. ICP10, ICP4, γ34.5 gene deletion. lacZ gene insertion into US10-12 locus.	Defective PKR signaling	NO	108	mouse models
	G207	γ34.5 deletion UL39 inactivation by insertion of lacZ gene	Defective PKR signaling	Paclitaxel and Adriamycin	109	in vitro and mouse models
	G47Δ	γ34.5, ICP47 and US11 promoter deletions UL39 inactivation by insertion of lacZ gene	Defective PKR signaling	NO	110	in vitro and mouse models